Assessing the Impact of the Axomove Therapy Medical Device on Low Back Pain Patients
AVA-PREPA
Assessment of the Impact of the Axomove Therapy® Medical Device on Subacute or Chronic Low Back Pain Patients Leaving Rehabilitation Centres to Facilitate Self-rehabilitation: a Multicentre Randomized Controlled Study.
1 other identifier
interventional
190
1 country
1
Brief Summary
An evaluation study of the impact of the Axomove Therapy® medical device on subacute or chronic low back pain patients leaving rehabilitation centres to facilitate self-rehabilitation. A prospective, randomized, open-label, multicentre study whose main objective is to evaluate the effectiveness of the Axomove Therapy Medical Device on disability reduction (Oswestry disability index score) patients with subacute or chronic low back pain requiring rehabilitation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable low-back-pain
Started Jun 2023
Typical duration for not_applicable low-back-pain
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 5, 2023
CompletedFirst Posted
Study publicly available on registry
June 18, 2023
CompletedStudy Start
First participant enrolled
June 28, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2024
CompletedJuly 21, 2023
April 1, 2023
1.2 years
April 5, 2023
July 19, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Efficacy of AXOMOVE Therapy
Functional capacity of patients measured through the Oswestry Disability Index score
14 weeks (105 days)
Secondary Outcomes (4)
Level of patient physical activity
day 0 (inclusion), day 15, day 45 and day 105
Quality of life
day 0 (inclusion), day 15, day 45 and day 105
Quality of life
day 0 (inclusion), day 15, day 45 and day 105
Efficacy of AXOMOVE Therapy
day 0 (inclusion), day 15, day 45
Study Arms (2)
AXOMOVE Therapy
EXPERIMENTALUse of a web and mobile application for remote monitoring and rehabilitation
Routine care
NO INTERVENTIONCurrent rehabilitation support care
Interventions
Personalized exercise programs for the self-rehabilitation of low back pain patients
Eligibility Criteria
You may qualify if:
- Patient aged 18-65 years,
- Patient agreeing to install the Axomove Therapy® application and agreeing to follow the study protocol,
- Patient with physical, sensory and cognitive ability to use an application (digital tools) on a smartphone, tablet or computer and perform physical exercise programs,
- A patient who is a member of, or in receipt of, a social security scheme.
You may not qualify if:
- Patients who are unable to understand, read or speak French,
- Inability to receive informed information,
- A patient with a sensory, visual or tactile impairment that prevents the correct use of a smartphone, tablet and/or computer, or prevents the exercise from being carried out safely,
- Patient with suspected or proven serious pathology such as recent vertebral fractures (less than 6 months), infection, malignant tumors and/or radiculopathy,
- Patient with a history of rheumatic inflammatory disease,
- Patient with true radiculalgia,
- Patient with scoliosis \> 30°, Patient with lumbar surgery in the past 12 months,
- Pregnant patient, parturient or breastfeeding,
- Patient under legal protection (guardianship, curatorship),
- A patient with a serious and/or uncontrolled illness that, in the opinion of the investigator, could result in unacceptable safety risks or compromise protocol compliance, for example: an active or uncontrolled infection.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Axomovelead
Study Sites (1)
CHRU de LILLE
Lille, 59000, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Valerie WIECZOREK, MD
CHU de Lille
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 5, 2023
First Posted
June 18, 2023
Study Start
June 28, 2023
Primary Completion
September 1, 2024
Study Completion
September 1, 2024
Last Updated
July 21, 2023
Record last verified: 2023-04
Data Sharing
- IPD Sharing
- Will not share